The global diabetes drug therapy market is expected to grow at a CAGR of 5.5% from 2021 to 2030. The growth of the market is attributed to the increasing prevalence of diabetes, rising awareness about the benefits of diabetes drugs, and technological advancements in drug development.
Glucagolike peptid1 (GL1) agonist is expected to be the fastest-growing type segment in terms of revenue during the forecast period. This growth can be attributed to their ability to lower blood glucose levels and reduce insulin resistance without causing hypoglycemia or weight gain. Dipeptidypeptidas4 (DP4) inhibitors are also expected to grow at a high rate due to their ability in lowering blood glucose levels and reducing insulin resistance without causing hypoglycemia or weight gain.
Type 1 Diabetes is projected as one of the fastest-growing applications for diabetes drugs during 2021-2030, owing primarily due its high incidence rates globally and lack of effective treatment options available for this condition.
Some Of The Growth Factors Of This Market:
- In addition, rising awareness about the benefits of these drugs among patients and physicians is also expected to fuel demand for these products in the near future.
- Furthermore, technological advancements in drug delivery systems such as inhalers and patches are anticipated to provide an impetus for growth in this market over the forecast period (2017-2022) 4) Increasing incidence rates for type 2 diabetes globally will drive demand for these drugs over the next few years.
Industry Growth Insights published a new data on “Diabetes Drug Therapy Market”. The research report is titled “Diabetes Drug Therapy Market research by Types (Glucagon-like peptide-1 (GLP-1) agonist , Dipeptidyl-peptidase-4 (DPP-4) inhibitors , Sodium glucose co-transporter 2 (SGLT2) inhibitors , Insulin , Others ), By Applications (Type 1 Diabetes , Type 2 Diabetes , Gestational Diabetes , Impaired Glucose Tolerance and Impaired Fasting Glycaemia ), By Players/Companies Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Novo Nordisk, Novartis International AG”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetes Drug Therapy Market Research Report
By Type
Glucagon-like peptide-1 (GLP-1) agonist , Dipeptidyl-peptidase-4 (DPP-4) inhibitors , Sodium glucose co-transporter 2 (SGLT2) inhibitors , Insulin , OthersÂ
By Application
Type 1 Diabetes , Type 2 Diabetes , Gestational Diabetes , Impaired Glucose Tolerance and Impaired Fasting GlycaemiaÂ
By Companies
Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Novo Nordisk, Novartis International AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Diabetes Drug Therapy Market Report Segments:
The global Diabetes Drug Therapy market is segmented on the basis of:
Types
Glucagon-like peptide-1 (GLP-1) agonist , Dipeptidyl-peptidase-4 (DPP-4) inhibitors , Sodium glucose co-transporter 2 (SGLT2) inhibitors , Insulin , OthersÂ
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type 1 Diabetes , Type 2 Diabetes , Gestational Diabetes , Impaired Glucose Tolerance and Impaired Fasting GlycaemiaÂ
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Mannkind Corporation
- Bristol Myers Squibb
- Medtronic
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline
- Sanofi
- Novo Nordisk
- Novartis International AG
Highlights of The Diabetes Drug Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glucagon-like peptide-1 (GLP-1) agonistÂ
- Dipeptidyl-peptidase-4 (DPP-4) inhibitorsÂ
- Sodium glucose co-transporter 2 (SGLT2) inhibitorsÂ
- InsulinÂ
- OthersÂ
- By Application:
- Type 1 DiabetesÂ
- Type 2 DiabetesÂ
- Gestational DiabetesÂ
- Impaired Glucose Tolerance and Impaired Fasting GlycaemiaÂ
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetes Drug Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetes drug therapy is the use of medications to control blood sugar levels in people with diabetes. These medications can help to reduce the amount of glucose in the blood, which can improve blood sugar control and help to prevent or delay diabetic complications.
Some of the major players in the diabetes drug therapy market are Abbott Laboratories, Mannkind Corporation, Bristol Myers Squibb, Medtronic, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Novo Nordisk, Novartis International AG.
The diabetes drug therapy market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diabetes Drug Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diabetes Drug Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diabetes Drug Therapy Market - Supply Chain
4.5. Global Diabetes Drug Therapy Market Forecast
4.5.1. Diabetes Drug Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diabetes Drug Therapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diabetes Drug Therapy Market Absolute $ Opportunity
5. Global Diabetes Drug Therapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diabetes Drug Therapy Market Size and Volume Forecast by Type
5.3.1. Glucagon-like peptide-1 (GLP-1) agonist
5.3.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
5.3.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
5.3.4. Insulin
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diabetes Drug Therapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diabetes Drug Therapy Market Size and Volume Forecast by Application
6.3.1. Type 1 Diabetes
6.3.2. Type 2 Diabetes
6.3.3. Gestational Diabetes
6.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diabetes Drug Therapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diabetes Drug Therapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diabetes Drug Therapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diabetes Drug Therapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diabetes Drug Therapy Demand Share Forecast, 2019-2026
9. North America Diabetes Drug Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diabetes Drug Therapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diabetes Drug Therapy Market Size and Volume Forecast by Application
9.4.1. Type 1 Diabetes
9.4.2. Type 2 Diabetes
9.4.3. Gestational Diabetes
9.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diabetes Drug Therapy Market Size and Volume Forecast by Type
9.7.1. Glucagon-like peptide-1 (GLP-1) agonist
9.7.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
9.7.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
9.7.4. Insulin
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diabetes Drug Therapy Demand Share Forecast, 2019-2026
10. Latin America Diabetes Drug Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diabetes Drug Therapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diabetes Drug Therapy Market Size and Volume Forecast by Application
10.4.1. Type 1 Diabetes
10.4.2. Type 2 Diabetes
10.4.3. Gestational Diabetes
10.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diabetes Drug Therapy Market Size and Volume Forecast by Type
10.7.1. Glucagon-like peptide-1 (GLP-1) agonist
10.7.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
10.7.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
10.7.4. Insulin
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diabetes Drug Therapy Demand Share Forecast, 2019-2026
11. Europe Diabetes Drug Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diabetes Drug Therapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diabetes Drug Therapy Market Size and Volume Forecast by Application
11.4.1. Type 1 Diabetes
11.4.2. Type 2 Diabetes
11.4.3. Gestational Diabetes
11.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diabetes Drug Therapy Market Size and Volume Forecast by Type
11.7.1. Glucagon-like peptide-1 (GLP-1) agonist
11.7.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
11.7.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
11.7.4. Insulin
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diabetes Drug Therapy Demand Share, 2019-2026
12. Asia Pacific Diabetes Drug Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diabetes Drug Therapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diabetes Drug Therapy Market Size and Volume Forecast by Application
12.4.1. Type 1 Diabetes
12.4.2. Type 2 Diabetes
12.4.3. Gestational Diabetes
12.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diabetes Drug Therapy Market Size and Volume Forecast by Type
12.7.1. Glucagon-like peptide-1 (GLP-1) agonist
12.7.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
12.7.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
12.7.4. Insulin
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diabetes Drug Therapy Demand Share, 2019-2026
13. Middle East & Africa Diabetes Drug Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diabetes Drug Therapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diabetes Drug Therapy Market Size and Volume Forecast by Application
13.4.1. Type 1 Diabetes
13.4.2. Type 2 Diabetes
13.4.3. Gestational Diabetes
13.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diabetes Drug Therapy Market Size and Volume Forecast by Type
13.7.1. Glucagon-like peptide-1 (GLP-1) agonist
13.7.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
13.7.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
13.7.4. Insulin
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diabetes Drug Therapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Diabetes Drug Therapy Market: Market Share Analysis
14.2. Diabetes Drug Therapy Distributors and Customers
14.3. Diabetes Drug Therapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mannkind Corporation
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Medtronic
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novo Nordisk
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis International AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
